ATE291922T1 - Makrolidcitrat-haltige formulierungen mit kontrollierter freisetzung - Google Patents

Makrolidcitrat-haltige formulierungen mit kontrollierter freisetzung

Info

Publication number: ATE291922T1
Authority: AT; Austria
Prior art keywords: controlled release; citrate; release formulations; formulations containing; macrolide
Prior art date: 2001-10-01

Application number

AT02256823T

Other languages

English (en)

Inventor

Hardeep Wadhwa

Original Assignee

Ind Swift Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-01

Filing date

2002-10-01

Publication date

2005-04-15

2002-10-01 Application filed by Ind Swift Ltd filed Critical Ind Swift Ltd

2005-04-15 Application granted granted Critical

2005-04-15 Publication of ATE291922T1 publication Critical patent/ATE291922T1/de

Links

239000003120 macrolide antibiotic agent Substances 0.000 title abstract 5
238000013270 controlled release Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title 1
150000001860 citric acid derivatives Chemical class 0.000 abstract 2
229940041033 macrolides Drugs 0.000 abstract 2
229960002626 clarithromycin Drugs 0.000 abstract 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000007909 solid dosage form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

AT02256823T 2001-10-01 2002-10-01 Makrolidcitrat-haltige formulierungen mit kontrollierter freisetzung ATE291922T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN1018DE2001		2001-10-01
IN1019DE2001		2001-10-01

Publications (1)

Publication Number	Publication Date
ATE291922T1 true ATE291922T1 (de)	2005-04-15

Family

ID=26324885

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02256823T ATE291922T1 (de)	2001-10-01	2002-10-01	Makrolidcitrat-haltige formulierungen mit kontrollierter freisetzung

Country Status (9)

Country	Link
US (1)	US6642276B2 (de)
EP (1)	EP1302205B1 (de)
JP (1)	JP2003212757A (de)
AT (1)	ATE291922T1 (de)
BR (1)	BR0208526A (de)
CA (1)	CA2405918A1 (de)
DE (1)	DE60203461T2 (de)
DK (1)	DK1302205T3 (de)
PT (1)	PT1302205E (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en)	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020068078A1 (en)	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US20050249786A1 (en) *	2001-09-28	2005-11-10	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20040185097A1 (en) *	2003-01-31	2004-09-23	Glenmark Pharmaceuticals Ltd.	Controlled release modifying complex and pharmaceutical compositions thereof
JP2006528689A (ja) *	2003-05-06	2006-12-21	ムルイェ、ニルマル	エリスロマイシン誘導体の徐放製剤
EP2535042A1 (de)	2003-06-16	2012-12-19	ANDRX Pharmaceuticals LLC.	Orale Makrolidusammensetzung mit erweiterter Freisetzung
WO2005004919A2 (en) *	2003-07-02	2005-01-20	Eurand, Inc.	Extended release systems for macrolide antibiotics
JP2006528190A (ja)	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質製剤、その使用法及び作成方法
EP1648418A4 (de)	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
EP1648415A4 (de)	2003-07-21	2011-11-16	Middlebrook Pharmaceuticals Inc	Antibiotisches produkt, seine verwendung und formulierung
US20050049209A1 (en) *	2003-08-06	2005-03-03	Chen Andrew Xian	Pharmaceutical compositions for delivering macrolides
AU2004264939A1 (en)	2003-08-11	2005-02-24	Middlebrook Pharmaceuticals, Inc.	Robust pellet
AU2004264356B2 (en)	2003-08-12	2011-01-27	Shionogi, Inc.	Antibiotic product, use and formulation thereof
JP5686494B2 (ja)	2003-08-29	2015-03-18	シオノギインコーポレイテッド	抗生物質製剤、その使用法及び作成方法
WO2005027877A1 (en)	2003-09-15	2005-03-31	Advancis Pharmaceutical Corporation	Antibiotic product, use and formulation thereof
US20050084540A1 (en) *	2003-10-17	2005-04-21	Indranil Nandi	Taste masking antibiotic composition
US8168228B2 (en) *	2003-10-17	2012-05-01	Sandoz Ag	Antibiotic clarithromycin micropellet compositions
US20050101547A1 (en) *	2003-11-06	2005-05-12	Sadatrezaei Mohsen	Stabilized azithromycin composition
BRPI0508743A (pt) *	2004-03-24	2008-01-22	Lupin Ltd	composição farmacêutica com uma liberação estendida de eritromicina ou um derivado da mesma, método para o uso de uma composição farmacêutica e processo para a preparação de uma composição farmacêutica
US8188067B2 (en)	2004-04-01	2012-05-29	Teva Pharmaceutical Industries Ltd.	Formulations of 6-mercaptopurine
KR20100045528A (ko) *	2004-04-01	2010-05-03	테바 파마슈티컬 인더스트리즈 리미티드	6-머캅토퓨린의 서방형 제제
CA2572292A1 (en)	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
JP5004236B2 (ja) *	2005-02-09	2012-08-22	キッセイ薬品工業株式会社	口腔内崩壊錠
US20070087056A1 (en) *	2005-08-09	2007-04-19	Claudia Guthmann	Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070087055A1 (en) *	2005-10-14	2007-04-19	David Jan	Directly compressible extended release alprazolam formulation
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en)	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US20070202164A1 (en) *	2006-02-28	2007-08-30	Hutchison Medipharma Enterprises Limited	Andrographis Extract Formulations
TW200800233A (en) *	2006-04-28	2008-01-01	Shionogi & Amp Co Ltd	A coated preparation of macrolide antibiotics
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (de) *	2007-08-17	2009-03-04	Abbott GmbH & Co. KG	Herstellung von Zusammensetzungen mit hauptsächlich nichtkristallinen eingebetteten Makrolid-Antibiotika
EP2110130A1 (de) *	2008-04-18	2009-10-21	Teva Pharmaceutical Industries Ltd.	Pharmazeutische Verwendung von 6-Mercaptopurin
CN101624412B (zh) *	2008-07-10	2012-07-04	刘力	大环内酯类衍生物及其制备和用途
EP2283824B1 (de)	2009-07-30	2017-04-19	Special Products Line S.p.A.	Zusammensetzungen und Formulierungen, die auf quellbaren Matrizen basieren, zur verzögerten Freisetzung von schlecht löslichen Arzneimitteln, wie zum Beispiel Clarithromycin
JP2013180961A (ja) *	2012-02-29	2013-09-12	Astellas Pharma Inc	Ｗｓ７２７７１３含有固形製剤
EP2671571A1 (de)	2012-06-05	2013-12-11	Sanovel Ilac Sanayi ve Ticaret A.S.	Formulierungen von Clarithromycin mit gesteuerter Freisetzung
CN103776945A (zh) *	2014-01-16	2014-05-07	扬子江药业集团南京海陵药业有限公司	罗红霉素胶囊的质量控制方法
WO2017066619A1 (en)	2015-10-16	2017-04-20	Teva Pharmaceutical Industries Ltd.	Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN105997929A (zh) *	2016-06-23	2016-10-12	南京华宽信息咨询中心	一种罗红霉素胶囊及其制备方法
CN106580903B (zh) *	2016-11-17	2019-12-13	江苏豪森药业集团有限公司	罗红霉素缓释药物组合物
CN109248155B (zh) *	2018-09-27	2020-08-11	北京鑫开元医药科技有限公司	一种罗红霉素胶囊及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE66143T1 (de) *	1985-01-11	1991-08-15	Abbott Lab	Feste zubereitung mit langsamer freisetzung.
US5457111A (en) *	1991-09-05	1995-10-10	Abbott Laboratories	Macrocyclic immunomodulators
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
US5750510A (en) *	1997-04-04	1998-05-12	Abbott Laboratories	3-descladinose-2,3-anhydroerythromycin derivatives
US6551616B1 (en) *	1997-04-11	2003-04-22	Abbott Laboratories	Extended release formulations of erythromycin derivatives
JPH10335732A (ja) *	1997-06-02	1998-12-18	Toshiba Microelectron Corp	レーザ用制御回路および制御方法
US6239112B1 (en) *	1998-07-09	2001-05-29	Merial, Inc.	Water miscible macrolide solutions
IT1303671B1 (it) *	1998-07-28	2001-02-23	Nicox Sa	Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
SI20150A (sl) *	1999-02-19	2000-08-31	Lek, Tovarna Farmacevtskih In	Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
TR200000054A2 (tr) *	2000-01-05	2001-08-21	Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇	Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.

2002
- 2002-09-30 CA CA002405918A patent/CA2405918A1/en not_active Abandoned
- 2002-09-30 US US10/261,564 patent/US6642276B2/en not_active Expired - Fee Related
- 2002-10-01 JP JP2002324526A patent/JP2003212757A/ja active Pending
- 2002-10-01 DE DE60203461T patent/DE60203461T2/de not_active Expired - Lifetime
- 2002-10-01 PT PT02256823T patent/PT1302205E/pt unknown
- 2002-10-01 DK DK02256823T patent/DK1302205T3/da active
- 2002-10-01 AT AT02256823T patent/ATE291922T1/de active
- 2002-10-01 BR BR0208526-7A patent/BR0208526A/pt active Search and Examination
- 2002-10-01 EP EP02256823A patent/EP1302205B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6642276B2 (en)	2003-11-04
DE60203461T2 (de)	2006-02-09
EP1302205B1 (de)	2005-03-30
DE60203461D1 (de)	2005-05-04
JP2003212757A (ja)	2003-07-30
DK1302205T3 (da)	2005-08-08
US20030077325A1 (en)	2003-04-24
BR0208526A (pt)	2004-08-10
PT1302205E (pt)	2005-06-30
CA2405918A1 (en)	2003-04-01
EP1302205A1 (de)	2003-04-16

Legal Events

Date

Code

Title

Description

2005-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1302205

Country of ref document: EP

Publication	Publication Date	Title
ATE291922T1 (de)	2005-04-15	Makrolidcitrat-haltige formulierungen mit kontrollierter freisetzung
AU2002357012A1 (en)	2003-06-10	Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
HUP0101237A1 (hu)	2001-09-28	Elnyújtott kioldódású gyógyszerkészítmények
NO20042565L (no)	2004-06-18	Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav
GB0100758D0 (en)	2001-02-21	Immunogenic complex method of preparation thereof and pharmaceutical compositions containing the same, useful for disease control
LTC1345910I2 (lt)	2022-06-10	Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
ATE317260T1 (de)	2006-02-15	Pharmazeutische formulierungen mit platinderivaten
DE60100186D1 (de)	2003-05-22	Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
DE69936002D1 (de)	2007-06-14	Angepasster löffel zur oralen medikamenten-verabreichung
WO2003002136A3 (en)	2004-03-04	Stable formulation of modified glp-1
EE05400B1 (et)	2011-04-15	Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
EE05081B1 (et)	2008-10-15	Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
HUP0402451A3 (en)	2008-04-28	Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
HUP0302319A3 (en)	2013-04-29	Pharmaceutical composition for oral administration of active ingredient
NO20040268L (no)	2004-03-23	Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
WO2001022791A3 (en)	2002-01-31	Controlled release compositions comprising nimesulide
ATA59499A (de)	2001-10-15	Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
IL159217A0 (en)	2004-06-01	An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
DE60131760D1 (de)	2008-01-17	Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
MXPA03002569A (es)	2003-10-14	Formulaciones de liberacion controlada para administracion oral.
FI20000780L (fi)	2001-10-04	Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ATE409474T1 (de)	2008-10-15	Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus
DE60316714D1 (de)	2007-11-15	Pharmazeutische formulierung enthaltend olanzapin
HUP0500958A2 (en)	2006-01-30	2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them, therapeutic use thereof and pharmaceutical compositions containing them
AU2001252741A1 (en)	2001-11-20	Pharmaceutical composition containing itraconazole with gastric ph-independentlyimproved solubility and preparation method thereof